Mankind Pharma to attend three investor conferences in September 2026
- Mankind Pharma management to attend three investor conferences in September 2026
- Events include Jefferies 5th India Forum in Gurgaon and J.P. Morgan conference in Mumbai
- Discussions restricted to public domain information and general business outlook
- No unpublished price sensitive information will be shared during meetings

*this image is generated using AI for illustrative purposes only.
Mankind Pharma Limited announced its management will participate in three investor conferences scheduled for September 2026.
The company disclosed the engagements pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Conference Schedule
The management officials will engage with investors and analysts through one-on-one or group meetings at the following events:
| Date | Event Name | City |
|---|---|---|
| September 17, 2026 | Jefferies 5th India Forum | Gurgaon |
| September 18, 2026 | Health care Forum | Mumbai |
| September 21, 2026 | J.P. Morgan India Conference | Mumbai |
Disclosure Guidelines
The company stated that no unpublished price sensitive information will be disclosed during these meetings. Discussions will be limited to general business outlook and information already available in the public domain.
The schedule remains subject to change due to exigencies on either side. The intimation has been uploaded on the company website.
Historical Stock Returns for Mankind Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.86% | -3.75% | -6.48% | +1.89% | -12.59% | 0.0% |
How might Mankind Pharma's strategic messaging at these September 2026 conferences influence its stock valuation in the subsequent quarter?
What specific growth initiatives or pipeline developments is the company likely to highlight to differentiate itself from competitors at the Jefferies and J.P. Morgan forums?
Could the management's engagement with global analysts signal an impending expansion into new international markets or partnerships?


































